Browsed by
Tag: Aubrey de Grey

U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017

U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017

 

The New Renaissance Hat

Listen to and download the audio recording of this panel discussion at http://rationalargumentator.com/USTP_Life_Extension_Panel.mp3 (right-click to download).

For its second expert panel, the U.S. Transhumanist Party invited Bill Andrews, Aubrey de Grey, Ira Pastor, and Ilia Stambler to discuss life extension and the quest to reverse biological aging through science and technology.

This two-hour panel discussion, moderated by Chairman Gennady Stolyarov II, took place on Saturday, February 18, 2017, at 10 a.m. U.S. Pacific Time. In this interactive venue, many opportunities for fresh discourse arose on the possibility of achieving dramatically greater longevity within our lifetimes. The substance of the discussion begins at 4:25 in the recording.

Questions the panelists considered include the following:

(i) How would you characterize the current state of efforts to reverse senescence / lengthen human lifespans?
(ii) How does progress in the areas of research you have delved into compare to your expectations approximately 10 to 15 years ago?
(iii) What are the most significant challenges and obstacles that you perceive to exist in the way of achieving serious reversal of biological aging?
(iv) What key technologies and methods of delivering treatments to patients would need to be developed in order for longevity escape velocity to be affordably achieved society-wide?
(v) What political reforms and societal / attitudinal changes would you advocate to accelerate the arrival of effective treatments to reverse biological aging and lengthen lifespans?
(vi) Are you concerned about any current political trends and how they might affect the progress of research into combating biological aging?
(vii) What can laypersons who are sympathetic to your goals do in order to hasten their realization? How can the effort to defeat aging become as popular and widely supported as efforts to defeat cancer and ALS are today?
(viii) What lessons can the history of anti-aging research offer to those who seek to advocate and help achieve effective scientific breakthroughs in this area in the coming years and decades?

Become a member of the U.S. Transhumanist Party for free. Apply here.

References

Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy” – Paper by Louise S. Hornstrup, Ruth Frikke-Schmidt, Børge G. Nordestgaard and Anne Tybjærg-Hansen. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:1441-1447, Originally published May 15, 2013.

Recognizing Degenerative Aging as a Treatable Medical Condition: Methodology and Policy” – Paper by Ilia Stambler. Aging and Disease.

***

Panelists

Dr. Bill Andrews is the President and CEO of Sierra Sciences – http://www.sierrasci.com/. As a scientist, athlete, and executive, he continually pushes the envelope and challenges convention. In his 35-year biotech career, he has focused the last 23 years on finding ways to extend the human lifespan and healthspan through telomere maintenance. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded 2nd place as “National Inventor of the Year” in 1997.

Dr. Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation – http://www.sens.org/. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

Ira Pastor has 30 years of experience across multiple sectors of the pharmaceutical industry, including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail. He is the CEO of BioQuark, Inc. – http://www.bioquark.com/ – and Executive Chairman of ReAnima Advanced Biosciences – https://reanima.tech/.

Dr. Ilia Stambler is a researcher at Bar Ilan University, Israel. His research focuses on the historical and social implications of aging and life-extension research. He is the author of A History of Life-extensionism in the Twentieth Century – www.longevityhistory.com. He is actively involved in advocacy for aging and longevity research – www.longevityforall.org.

Discussion on Life-Extension Advocacy – G. Stolyarov II Answers Audience Questions

Discussion on Life-Extension Advocacy – G. Stolyarov II Answers Audience Questions

The New Renaissance Hat

G. Stolyarov II

******************************

Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, answers audience questions regarding life-extension advocacy and possibilities for broadening the reach of transhumanist and life-extensionist ideas.

While we were unable to get into contact with our intended guest, Chris Monteiro, we were nonetheless able to have a productive, wide-ranging discussion that addressed many areas of emerging technologies, as well as trends in societal attitudes towards them and related issues of cosmopolitanism, ideology, and the need for a new comprehensive philosophical paradigm of transmodernism or hypermodernism that would build off of the legacy of the 18th-century Age of Enlightenment.

Become a member of the U.S. Transhumanist Party for free. Apply here.

An Example of the Glaring Lack of Ambition in Aging Research – Post by Reason

An Example of the Glaring Lack of Ambition in Aging Research – Post by Reason

The New Renaissance HatReason
******************************

The mainstream of aging research, at least in public, is characterized by a profound lack of ambition when it comes to treating aging as a medical condition. Researchers talk about slightly altering the trajectory of aging as though that is the absolute most that is possible, the summit of the mountain, and are in many cases ambivalent when it comes to advocating for even that minimal goal. It is this state of affairs that drove Aubrey de Grey and others into taking up advocacy and research, given that there are clear paths ahead to rejuvenation, not just a slight slowing of aging, but halting and reversing the causes of aging. Arguably embracing rejuvenation research programs would in addition cost less and take a much shorter span of time to produce results, since these programs are far more comprehensively mapped out than are efforts to produce drugs to alter the complex operations of metabolism so as to slightly slow the pace at which aging progresses. It is most frustrating to live in a world in which this possibility exists, yet is still a minority concern in the research community. This article is an example of the problem, in which an eminent researcher in the field takes a look at a few recently published books on aging research, and along the way reveals much about his own views on aging as an aspect of the human condition that needs little in the way of a solution. It is a terrible thing that people of this ilk are running the institutes and the funding bodies: this is a field crying out for disruption and revolution in the name of faster progress towards an end to aging.

How can we overcome our niggling suspicion that there is something dubious, if not outright wrong, about wanting to live longer, healthier lives? And how might we pursue longer lives without at the same time falling prey to quasiscientific hype announcing imminent breakthroughs? In order to understand why aging is changing, and what this means for our futures, we need to learn more about the aging process itself. As a biologist who specializes in aging, I have spent more than four decades on a quest to do exactly this. Not only have I asked why aging should occur at all (my answer is encapsulated in a concept called disposability theory), but I have also sought to understand the fastest-growing segment of the population – those aged 85 and above. The challenges inherent in understanding and tackling the many dimensions of aging are reflected in a clutch of new books on the topic. Are these books worth reading? Yes and no. They take on questions like: Can we expect increases in human longevity to continue? Can we speed them up? And, on the personal level, what can we do to make our own lives longer and healthier? If nothing else, these books and their varied approaches reveal how little we actually know.

To find out more about factors that can influence our individual health trajectories across ever-lengthening lives, my colleagues and I began, in 2006, the remarkable adventure of the still ongoing Newcastle 85+ Study, an extremely detailed investigation of the complex medical, biological, and social factors that can affect a person’s journey into the outer reaches of longevity. For each individual, we determined whether they had any of 18 age-related conditions (e.g., arthritis, heart disease, and so on). Sadly, not one of our 85-year-olds was free of such illnesses. Indeed, three quarters of them had four or more diseases simultaneously. Yet, when asked to self-rate their health, an astonishing 78 percent – nearly four out of five – responded “good,” “very good,” or “excellent.” This was not what we had expected. The fact that these individuals had so many age-related illnesses fit, of course, with the popular perception of the very old as sadly compromised. But the corollary to this perception – that in advanced old age life becomes a burden, both to the individuals themselves and to others – was completely overturned. Here were hundreds of old people, of all social classes and backgrounds, enjoying life to the fullest, and apparently not oppressed by their many ailments.

As for my stake in the enterprise, I began investigating aging when I was in my early 20s – well before I had any sense of my own body aging. Quite simply, I was curious. What is this mysterious process, and why does it occur? Everything else in biology seems to be about making things work as well as they can, so how is it that aging destroys us? Now that I am growing older myself, my research helps me understand my own body and reinforces the drive to live healthily – to eat lightly and take exercise – though not at the cost of eliminating life’s pleasures. For all that I have learned about aging, my curiosity remains unabated. Indeed, it has grown stronger, partly because as science discovers more about the process, it reveals that there is ever more to learn, ever greater complexity to unravel, and partly because I am now my own subject: through new physical and psychological experiences in myself, I learn more about what older age is really like. I know all too well that the next phase of my life will bring unwelcome changes, and of course it must end badly. But the participants of the Newcastle 85+ Study have shown me that the journey will not be without interest.

Link: https://lareviewofbooks.org/article/want-live-longer-complicated-relationship-longevity/

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

The New Renaissance HatReason
******************************

As I mentioned last week, earlier this year Fight Aging! invested a modest amount in the Ichor Therapeutics initiative to develop a treatment for macular degeneration, joining a number of other amateur and professional investors in helping to get this venture started. The approach taken here is based on the results of research carried out at the Methuselah Foundation and SENS Research Foundation over much of the past decade, funded by philanthropists and the support of our community of longevity science enthusiasts. This is how we succeed in building the future: medical science in the laboratory leads to medical development in startup companies, each new stage bringing treatments capable of repairing specific forms of age-related molecular damage that much closer to the clinic.

Ichor Therapeutics is one of a growing number of success stories to emerge from the SENS rejuvenation research community. Young scientists, advocates, and donors involved in earlier projects – years ago now – have gone on to build their own ventures, while retaining an interest in stepping up to do something meaningful to help bring an end to aging. Back in 2010, Kelsey Moody worked on the LysoSENS project to find ways to break down damaging metabolic waste in old tissues; fast-forward six years, and he is the now the CEO of a successful small biotechnology company with a great team, taking that very same technology and putting it to good use. I recently had the chance to ask Kelsey a few questions about the future of SENS rejuvenation research, as well as how the Ichor scientists intend to construct a new class of therapy for macular degeneration, one based on removing one of the root causes of the condition.

Quote:

Who are the people behind Ichor Therapeutics? How did you meet and decide that this was the thing to do? Why macular degeneration as a target?

People have always been the focus of Ichor. Since day one we have worked to create a positive environment that cultivates a product-oriented research focus and emphasizes autonomy and personal accountability for work. As a result, ambitious self-starters tend to find their way to Ichor and remain here. However, we recognized early on that just filling a lab with a bunch of blue-eyed bushy tailed young up-and-comers is not sufficient to develop a robust, mature, translational pipeline. We have augmented our team with a number of critical staff members who are seasoned pharma operators, including our Quality Assurance Director and General Counsel.

Age-related macular degeneration (AMD) was chosen as a target because we believe it is the closest SENS therapy to the clinic. While we obviously have an interest in providing cures for the patients suffering from AMD and are attracted to the large market opportunities such a treatment could bring, our broader interest is in validating the entire SENS paradigm. We believe that Aubrey de Grey continues to receive excessive criticism because nothing spun out of SENS has ever made it into a legitimate pre-clinical pipeline, much less to the bedside. However, this does not mean he is wrong. Our goal is to be the first group to bring a SENS inspired therapy into the clinic and in doing so, silence critics and generate new energy and capital for this cause.

I understand there’s a lengthy origin story for the approach you are taking to treat AMD; it’d be great to hear some of it.

Our approach to treating AMD is based on the hypothesis that cellular junk that accumulates over the lifespan significantly contributes to the onset and progression of AMD. Our goal is to periodically reduce the burden of the junk so it never accumulates to levels sufficient to induce pathology. The strategy to accomplish this calls for the identification of enzymes that can break down the junk in a physiological setting, and the engineering of these enzymes such that they can break down the target in the correct organelle of the correct cell without appreciable collateral damage to healthy cells or tissue.

Methuselah Foundation and SENS Research Foundation did excellent work in establishing this program nearly a decade ago. They successfully identified a number of candidate enzymes that could break down the molecular junk, but reported that the targeting systems evaluated failed to deliver these enzymes to the appropriate organelles and cells. My group reevaluated these findings, and discovered that these findings were flawed. The delivery failure could be entirely attributed to a subtle, yet highly significant difference between how the target cells behave outside of the body as compared to inside the body. It turned out that the approach was in fact valid, it was the cell based assay that had been used that was flawed. This discovery was striking enough that SENS Research Foundation provided Ichor with funding and a material and technology transfer agreement to reassess the technology, and over $700,000 in directed program investments and grants have been received in the last year or two.

You recently completed a round of funding for the AMD work; what is the plan for the next year or so?

The new funds will allow us to develop a portfolio of enzyme therapy candidates to treat AMD. We will obtain critical data necessary to secure follow-on investment including in vitro studies (cell culture studies to confirm mechanism of action and cytotoxicity) and pivotal proof-of-concept in vivo studies, such as toxicity, PK/PD (how long the enzyme stays in the body and where), and efficacy. We will also be restructuring the company (reincorporating an IP holding company in Delaware, ensuring all contracts are up to date and audited) and ensuring our IP position is on solid footing (licensing in several related patents from existing collaborators, and filing several provisional patents from our intramural work). Collectively, we believe these efforts will position us to obtain series A for investigational new drug (IND) enabling pre-clinical studies.

You’ve been involved in the rejuvenation research community for quite some time now. What is your take on the bigger picture of SENS and the goal of ending aging?

This is a loaded question. What I can say is that the medical establishment has made great progress in the treatment of infectious disease through the development of antibiotics, vaccines, and hygiene programs. However, similar progress has not been realized for the diseases of old age, despite exorbitant expenditures. I have chosen to work in this space because I think a different approach is necessary, and it is here that I believe my companies and I can be the most impactful. I think SENS provides a good framework within which to ask and answer questions.

What do you see as the best approach to getting nascent SENS technologies like this one out of the laboratory and into the clinic?

We need more people who fully understand, in a highly detailed way, what a real translational path looks like. To take on projects like this, being a good scientist is not enough. We need people who can speak business, science, medicine, and legal, and apply these diverse disciplines to a well articulated, focused product or problem. There is no shortage of people who partially understand some of these, but the details are not somewhat important – they are all that matter for success in this space.

Another area is for investors. Some of the projects that come across my desk for review are truly abysmal, yet I have seen projects that are clearly elaborate hoaxes or outright scams (to anyone who has stepped foot in a laboratory) get funded to the tune of hundreds of thousands of dollars or more. While it is perfectly reasonable for high net worth individuals to gamble on moon shots in the anti-aging space (and I am ever grateful for the investors who have taken such a gamble on us) even aggressive development strategies should have some basis in reality. This is especially true as more and more high tech and internet investors move into the space.

If this works stupendously well, what comes next for Ichor Therapeutics?

I really want to get back into stem-cell research, but I basically need a blank check and a strong knowledge of the regulatory path to clinic before I feel comfortable moving into the space. A successful AMD exit would accomplish both of these goals, and position us to pivot to cell-based therapies.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
Aubrey de Grey at the Launching Longevity Panel, and Announcing Acceptance of the First Paper to be Published on MitoSENS Research – Article by Reason

Aubrey de Grey at the Launching Longevity Panel, and Announcing Acceptance of the First Paper to be Published on MitoSENS Research – Article by Reason

The New Renaissance HatReason
******************************

Today I’ll direct your attention to a couple of videos, thematically linked by the presence of Aubrey de Grey, cofounder of the SENS Research Foundation and tireless advocate for progress towards working rejuvenation therapies. For the first of the videos, de Grey recently took part in a panel discussion involving representatives of the biotechnology industry, the research establishment, and venture capital community, with the topic being the coming development of a new industry that will develop therapies to extend healthy life and turn back aging. That industry has barely started to form its earliest and smallest stage today, as the first lines of rejuvenation research reach the point of commercial viability. There are a few startups and a lot of deep pockets yet to be convinced that this is going somewhere – though the commentary in the panel is encouraged, considering those involved.

The recent Rejuvenation Biotechnology 2016 conference hosted by the SENS Research Foundation was more along the same lines, focused on creating a foundation for the near future industry that will build and provide rejuvenation therapies. The purpose of the conference series is to help smooth the way for these treatments to move rapidly from the laboratory to the clinic, to build the necessary relationships, manage expectations, and pull in the additional support needed to make best possible progress. The conference was livestreamed over the past couple of days, and at one point Aubrey de Grey announced the just-then-and-there acceptance of the first scientific publication for the MitoSENS team at the SENS Research Foundation. They are presently in the lead, at the cutting edge, among the few groups working on the project of copying mitochondrial genes into the cell nucleus to protect them from the damage of aging. Ultimately, copying all thirteen genes should completely remove the contribution of mitochondrial damage to degenerative aging, as mitochondria will no longer become dysfunctional as their local DNA is damaged. They will get the proteins they need from the cell nucleus instead. It is a worthy project, and it is always welcome to see progress on this front.

Launching Longevity: Funding the Fountain of Youth

 

Can technology make human longevity a reality? As the pace of discovery accelerates, scientists and entrepreneurs are closing in on the Fountain of Youth. Disrupting the aging process by hacking the code of life, promises better health and longer maximum lifespans. With many layers of complexity from science to ethics, there are still skeptics placing odds against human longevity. Venture capitalists are betting on success; putting big money on the table to fund longevity startups. Google/Alphabet and drugmaker AbbVie have invested $1.5 billion on Calico, while Human Longevity Inc. recently raised $220 million from their Series B funding round. Complementing traditional venture investment, VCs like Peter Thiel and Joon Yun have established foundations and prizes to accelerate the end of aging. Why are VCs suddenly investing heavily in longevity startups? Will extended lifespan be a privilege of the wealthy or will the benefits be accessible to all? How long before these well-funded startups bring viable products to market?

 

Aubrey de Grey Announces Progress in MitoSENS

 

Ok everybody, before I introduce the next session I just wanted to make a very small, brief, but very welcome announcement. Literally half an hour ago we received some extremely good scientific news. Those of you who have been following SENS research since before the SENS Research Foundation itself even existed will know that, about a decade ago, the very first project, the very first research program that we were able to initiate – with the help of, especially, the initial donation of Peter Thiel – was to make mitochondrial mutations harmless by essentially putting backup copies of the mitochondrial DNA into the nuclear genome, modified in such way of course that the encoded proteins would be colocated back into the mitochondria to do their job. This is an idea that was first put forward more than 30 years ago, but it is an idea that despite quite a bit of initial effort, nobody was able to make work. When I first came across this concept, in fact I’d thought of it myself, it’s a pretty obvious idea really, I came to the conclusion that a lot of the despair and despondency and pessimism about this approach was premature, and that it was worth having another go, and so that was the very first project we decided to fund.

Suffice to say that it has not been quite as easy as I was hoping to make progress in that space, but progress has now been made, step by step, over the past several years, with the help especially of the absolutely amazing team we have at the research center, who work on this, headed by Matthew O’Connor. Amutha Boominathan is the number two on the team, and is absolutely indispensable, I’ve no idea where we’d be without her. So, what’s happened half an hour ago is that for the very first time in the entire history of this project, we have got far enough to have a paper accepted in a very nice journal, Nucleic Acids Research, which reports on our progress in this area. The headline result in this paper is that we are the first team ever to get two of the proteins encoded by genes in the mitochondrial DNA simultaneously functioning in the same cell line, and of course – two is equivalent to infinity for mathematicians, you know that, right? – this is extremely heartening news, and I just wanted to let you all know, thank you.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
G. Stolyarov II Interviews Demian Zivkovic Regarding the D.N.A. – Gene Therapies Congress

G. Stolyarov II Interviews Demian Zivkovic Regarding the D.N.A. – Gene Therapies Congress

The New Renaissance Hat
G. Stolyarov II and Demian Zivkovic
******************************

Mr. Stolyarov invited Demian Zivkovic, President of the Institute of Exponential Sciences (IES), to discuss the forthcoming Designing New Advances (D.N.A.) Gene Therapies Congress in Utrecht, The Netherlands.

The interview took place on Sunday, June 19, 2016, at 11 a.m. US Pacific Time. Watch the recording here.

The D.N.A. Congress is scheduled to occur on July 9, 2016, and will feature speakers such as Oliver Medvedik, Aubrey de Grey, Elizabeth Parrish, Keith Comito, and Tatjana Kochetkova. This event receives the strong endorsement of both The Rational Argumentator and the Nevada Transhumanist Party.

Read the announcement of the D. N. A. Congress here.

Contribute to the fundraiser for the D. N. A. Congress on Indiegogo  and Generosity.

DNA_Interview_CoverDemian Zivkovic is the president of the Institute of Exponential Sciences  (Facebook  / Meetup) – an international transhumanist think tank / education institute comprised of a group of transhumanism-oriented scientists, professionals, students, journalists, and entrepreneurs interested in the interdisciplinary approach to advancing exponential technologies and promoting techno-positive thought. He is also an entrepreneur and student of artificial intelligence and innovation sciences and management at the University of Utrecht.

Demian and the IES have been involved in several endeavors, such as organizing lectures on exponential sciences, interviewing experts such as Aubrey de Grey, joining several of Mr. Stolyarov’s futurism panels, and spreading Death is Wrong – Mr. Stolyarov’s illustrated children’s book on indefinite life extension – in The Netherlands.

Demian Zivkovic is a strong proponent of healthy life extension and cognitive augmentation. His interests include hyperreality, morphological freedom advocacy, postgenderism, and hypermodernism. He is currently working on his ambition of raising enough capital to make a real difference in life extension and transhumanist thought.

D.N.A. Congress Announcement by the Institute of Exponential Sciences

D.N.A. Congress Announcement by the Institute of Exponential Sciences

The New Renaissance HatInstitute of Exponential Sciences
******************************
 

Editor’s Note: The forthcoming D.N.A. Congress in Utrecht, The Netherlands, hosted by the Institute of Exponential Sciences, devoted to discussions of gene therapies, receives the strong endorsement of both The Rational Argumentator and the Nevada Transhumanist Party. The D.N.A. Congress offers a promising venue to discuss the potential for gene therapies to cure diseases, lengthen lifespans, and improve quality of life for millions of people in the coming years and decades.

~ Gennady Stolyarov II, Editor-in-Chief, The Rational Argumentator, June 5, 2016

D.N.A CONGRESS PRESS RELEASE:

The Institute of Exponential Sciences (IES) has a large announcement to make. We are organising D.N.A – The largest European congress on human gene therapies, featuring speakers such as Aubrey de Grey, Liz Parrish, Oliver Medvedik and others.

Our event has been endorsed by LEAF, Heales VZW, BioViva, SENS Research Foundation, Singularity Network, People Unlimited, The Rational Argumentator, and many others. The event will be covered by national media and will be broadcasted online.

To make this vision a reality, we need your support. Share this message and donate today. Thank you!

IES needs your support to help make this vision a reality. Click here to donate to our crowdfunding campaign.

D.N.A – Designing New Advances: The second large Institute of Exponential Sciences event is coming to Utrecht

 

DNADemian Zivkovic

Utrecht – After a successful event last year in May, the grand congress is ready for a second edition. With a new name, we hope to make exponential sciences more approachable to the general public and bring people in the field closer together. The Institute of Exponential Sciences congress 2016 will be held at RASA podium on the 9th of July. The main theme of the event is gene therapies and cutting-edge applications of such therapies, such as health extension and interventions against human aging. To guarantee a great event, we have invited some of the biggest names in the field. Our guest speakers will be as follows:

Opening the event will be Oliver Medvedik, Ph.D, director of scientific programs at Genspace. Dr. Medvedik has earned his Ph.D at Harvard Medical school in the biomedical and biological sciences program. Since graduating from Harvard, he has worked as a biotechnology consultant, taught molecular biology to numerous undergraduates at Harvard, and mentored two of Harvard’s teams for the international genetically engineered machines competition (IGEM) held annually at M.I.T.

Our second speaker is Aubrey David Nicholas Jasper de Grey, Ph.D, an English author, Chief Science Officer of the SENS Research Foundation, and editor-in-chief of the academic journal Rejuvenation Research. Aubrey de Grey is well known for his focus on regenerative medicine and views on human aging. He will take the stage talking about the applications of current and upcoming technologies and studies which hold the potential to greatly extend our healthy lifespan.

Our third speaker is Tatjana Kochetkova, Ph.D, who is a fellow of the Institute of Exponential Sciences and a bioethicist. Dr. Kochetkova will follow up discussing the ethical and philosophical side of the technology and will address questions of what exponential technologies in biotech mean for society.

Our fourth speaker is Elizabeth Parrish, a fellow of the Institute of Exponential Sciences and the Founder and CEO of BioViva Sciences Inc, a Delaware corporation based in Seattle, WA, with labs and participating clinics in South/Central America where the majority of practical work is carried out. BioViva has been noted for being the first corporation in the world to treat a patient with gene therapy to reverse aging. The woman who wants to genetically engineer you will cover the basics of BioViva’s approach and vision for the the future, as well as the potential that gene therapies hold for radically improving our health and lives in the future.

Our fifth speaker will be Keith Comito, who is the founder and president of the Life Extension Advocacy Foundation (LEAF), a 501(c)(3) non-profit organization and a partner of the Institute of Exponential Sciences. Through LEAF, he operates the crowdfunding platform Lifespan.io, which supports biomedical research aimed at extending healthy human lifespan. He also serves as policy coordinator for the Global Healthspan Policy Institute, which facilitates relationships between researchers and government to advance initiatives in support of healthy life extension.

About Institute of Exponential Sciences

The Institute of Exponential Sciences is an international innovation-oriented think tank, outreach organisation, and networking platform based in the Netherlands, in the city of Utrecht. Its main activities include organising lectures and conferences, providing quality consultancy on innovation and exponential technologies, and collaborating with student organisations and universities in educating the public on the importance of exponential technologies.

It was founded by members of its predecessor, the Arma’thwynn society, which was a student group of like-minded young academics in the Netherlands. After organising events and attracting a very diverse and professional team of entrepreneurs, academics, and journalists, the society decided to move past student politics and make the move towards professionalism.

The Institute of Exponential Sciences is the result of that decision. After organising successful events (the largest of which was their symposium in April, 2015), the Institute of Exponential Sciences formalised its mission and reached out towards a process of international collaboration with other entities which share a techno-positive vision. The institute strives towards excellence in providing the best information and resources related to the issues relevant in the rapidly advancing technological society we live in.

The IES approach is focused on providing interdisciplinary education in the fields of exponential technologies such as artificial intelligence, bio-informatics, gene therapies, 3D-printing, augmented reality, and neural interfacing. We also provide a networking platform which allows entrepreneurs, scientists, journalists, and students to get in touch with others with similar ideas so that they may create the technologies of tomorrow. The IES strives not only to improve the speed of development of these technologies, but also to show the public the amazing possibilities technology provides for society.

IES and the IES logo are either registered trademarks or trademarks of IES Foundation in the Netherlands and/or other countries. All other products and/or services referenced are trademarks of their respective entities.

The Role of Aging in Society – Article by Demian Zivkovic

The Role of Aging in Society – Article by Demian Zivkovic

The New Renaissance HatDemian Zivkovic
******************************
Take the following situation. We discover an extremely contagious virus. It infects you and your loved ones, and quickly propagates through all of mankind. As a result, 150,000 people die every day. It kills more than twice the number killed in the Holocaust every three months, and in 30 years, it will have killed 1.5 billion, around one in six people. How high would this score on a list of global priorities? There’s no doubt the situation would be grave. Most people would demand immediate action.
***
But that’s just a thought experiment, right? Not really. Every day, 150,000 people do die from age-related disease. Not only the cost in lives is monumental; societal and economic costs are also on the rise. According to the Dutch Statistics Authority (the CBS), the amount of people older than 65 (retirement age) will have increased to 27% in 2040, from the current 19%. As more people are born, this also means more people die from age-related disease, taking all their knowledge, expertise, and productivity with them. In short: If we don’t do anything about the consequences of our aging population, we face severe consequences.
 *** 

So what is the best way to deal with the problem of our society aging?

There is no simple solution. More conventional healthcare barely improves quality of life, while just letting people die is not an ethical option. Rutger Bregman, a Dutch historian and philosopher, argues for thinking more radically about solutions to societal problems. According to his essay “Een pleidooi voor de utopie” (A plea for utopia) in the Dutch magazine “De groene Amsterdammer”, we have lost the ability to think in such a way; We only look at marginal improvements, instead of looking at changes that could radically improve and change our society. So if we do explore more radical solutions, what can we do?

Professor Aubrey de Grey, Ph.D. in biology, Chief Science Officer of the prestigious SENS Research Foundation, and partner at the Gerontological Society of America, argues that we could look at a radical intervention in human aging. According to de Grey, the best way of solving many of these problems is to cure aging at its source. De Grey is not the only one who holds that opinion. Alphabet, Inc.‘s biotechnology subsidiary (Calico) also views the problem from this position. This point of view obviously raises quite a few questions. Critics claim that de Grey’s vision is impossible or undesirable. Proponents point to the massive advantages of curing age-related disease.

One of the arguments put forward is that short-term thinking causes many economical and societal problems. Economist Joseph Stiglitz speaks about rent-seeking (“Rent-Seeking and the Making of an Unequal Society”, 2014), economically destructive behaviour in which an individual or business enriches itself while harming the entire economy in the process. Environmental concerns are also a very large issue. Since people (if they are lucky) don’t get to live much longer than a hundred years old, many people find it very uninteresting to think about what our behaviour is doing to the environment on the long term. But what will it mean for these problems if we have to let go of short-term thinking, because we live for a much longer time? One thing is for sure: If de Grey’s vision becomes reality, a lot will change in our society.

Economy, Environment, and Overpopulation
 *** 

Short-term thinking has a catastrophic effect on our economy and environment.

The previously mentioned economist Joseph Stiglitz claims in his article that our economy is suffering serious problems, since rent-seeking is causing society-wide destruction and inequality. For centuries, economists, philosophers, and ethicists have been considering how to stop such unethical behavior. Usually, they looked at different moral developments, better regulations, or restructuring society as solutions.

In his work “The Power of Context”, Malcolm Gladwell makes the claim that the environment and the context we live in have a large impact on our behaviour. Human life knows a few certainties; one of them is that you will die within a century. One may have children or grandchildren, but very few people are concerned about the fate of their heir several hundred generations down the road. In my interview with him (2014, Nakedbutsafe magazine), Professor de Grey argues that many people would be much more concerned with the long term if they knew they would still be around in several centuries, and there’s a lot to be said about that. Instead of waging a fruitless and hopeless war on selfishness, it may be more prudent to use it to improve the world.

De Grey’s solution essentially means inventing the fountain of youth through advanced biotechnology. He wants to do this through a method called “Strategies for Engineered Negligible Senescence” or SENS. SENS essentially involves periodically repairing accumulated damage from aging, so it never reaches a critical point where it turns into a specific illness. De Grey is not the only one who is looking for a solution for aging: Google Ventures heavily invests in such technology.

In 2013, Google founded a company called Calico, which entered a partnership with AbbVie. With a record investment of two billion dollars, most money ever put into a start-up, the ambitious firm wants to create a fundamental understanding of aging and use said understanding to eventually cure said aging. Bill Maris, president of Google Ventures, has already made the famous claim we will be able to have technology to live 500 years within our lifetimes. Another actor in the corporate sector is BioViva, whose CEO, Elizabeth Parrish, has become the first human on the planet to get treated with a combination of in vivo gene therapies to slow down aging.

The approaches of Calico, SENS, and BioViva look at the problem from different angles, but they have one thing in common: they are not looking at ways to extend the lives of sick, disabled seniors. Instead, they are looking at a method to not simply extend life, but to extend health. They are looking at methods to stop this biological aging from happening. Life extension is merely a side effect. After all, if a 200-year-old has the vitality of a 40-year-old, why would an aging population be a problem? Even though the population will age, the percentage of “elderly” people will decrease, and so will age-related suffering and related economic pressure.

However, not everyone is optimistic about these changes. Critics are concerned about what a radically extended life will mean for overpopulation. They argue that if nobody dies, we will have so many people that we will either have to kill people, or make reproduction illegal. While such a top-down approach may seem like “common sense”, there’s a lot to be said about why such drastic top-down measures will be unnecessary. Steven Johnson, a best-selling popular science author and media theorist, introduces the concept of emergence (Emergence: The Connected Lives of Ants, Brains, Cities, and Software, 2001). Emergence refers to patterns in complex systems which can’t be reduced to the properties or behaviours of an individual element of the system. Johnson uses the ant colony as an example: while no single ant coordinates the behaviour of the colony, the entire system is self-organizing and thus functions perfectly. An ant colony, but even more so human society, is a good example of an emergent system.

A simple example of this self-organization is the distribution of bread. There is no central authority that plants where bakeries should be located, how much grain should be produced, what logistic solutions should be used for bread transport to people’s homes, or what bread prices ought to be. In fact, such central planning has been tried several times in history. In communist dictatorships such as the Soviet Union and North Korea, centralized attempts at steer society have had catastrophic results. However, if emergence of self-organisation does its job, a society flourishes. We can see this same effect work on overpopulation and birth rates. According to the World Health Organisation, the fertility rates plummet as life expectancy skyrockets. Countries that have the highest life expectancies have the lowest birth rates. Japan, which has one of the highest life expectancies has a negative birth rate; its population is in decline, even though no central planning has intervened in any way.

This hypothesis is also supported by virtually all historic trends. Every widespread average life-expectancy spike was met with a plummet in birth rates. When our life expectancy went up because of the invention of antibiotics, our birth rates hit historic lows. We see the opposite in countries where life expectancy is very low. The country with the highest birth rate is Nigeria, while it’s one of the poorest countries in the world. The average life expectancy in Nigeria is below 55. According to the United Nations, countries with low life expectancy have by far the largest effect on overpopulation.

Regulation of population is therefore unnecessary; a complex system such as modern society self-regulates and corrects itself. This idea is in line with Gladwell’s theory of context-dependent behavior; the context largely defines our behavior. And as a self-organizing system, society demonstrably changes the context to steer our behavior in effective patterns. A dystopia where government has to regulate reproduction or death is very unlikely.

Philosophical Arguments

If Gladwell is right about context as catalyst of behaviour, what will the effects of a society devoid of biological aging be on our humanity? Not all arguments against radical life extension are pragmatic in nature. The conservative bioethicist Leon Kass is one of the opponents of radical life extension pondering this question. He argues that indefinite life extension is unnatural and thus undesirable. Kass also claims that we won’t appreciate life if we life “forever.”

“Time is a gift, but the perception of endless time or of time without bound in fact has the possibility of undermining the degree to which we take time seriously and make it count.”

~ Leon Kass (Aging Research, 2004).

Kass makes a comparison with the ancient Greek gods to argument why life’s shortness gives it purpose.

Homer in The Iliad and The Odyssey presents human beings whom he names as mortals. That is their definition in contrast to the immortals. And the immortals for their agelessness and their beauty live sort of shallow and frivolous lives. Indeed, they depend for their entertainment on watching the mortals who, precisely because they know that their time is limited, and that they go around only once, are inclined to make time matter and to aspire to something great for themselves.

~ Leon Kass (Aging Research, 2004)

While these arguments may seem somewhat of a philosophical take on many common criticisms, they are easily debunked. Elizabeth Parrish, CEO of BioViva and a pioneering entrepreneur in the field of gene therapy, argues against the idea that we should accept something because it’s considered “normal.” (“Liz Parrish speaks at People Unlimited on transcending the aging paradigm with gene therapy”, 2015). She argues that “normal” is a situational opinion which constantly changed throughout the entirety of history. In 1665, dying of infectious disease was normal. During this time only one percent of all humans died from aging: Infectious diseases were responsible for more than three quarters of all deaths before we developed the first immunization therapies – the development of which is similar to the process to defeat aging with gene therapy today. Just like today, there was criticism of the development of vaccines and antibiotics, even though lifespans and health were greatly improved by the use of these advancements – and the arguments have stayed very much the same.

Parrish is not the only one who provides a strong argument against the vision of Kass. Reason, creator of the Fight Aging! blog, is another intellectual who is very skeptical about Kass’s position. In his rebuttal of Kass (“Leon Kass, Mystic” by Reason, 2004), he compares Kass with an alchemist, a modern mystic:

“The alchemists of old stood atop what little knowledge of chemistry they had and built a speculative religion of hermetic magic, transient wishes, celestial signs and hidden gold. Leon Kass stands atop what little biotechnology we have today (and seems to have a good grasp thereof), building his own structures of fanciful thought, equally disconnected from the real world. 

All of Kass’ arguments against longer, healthier lives are essentially mystical and devoid of real substance.”

In “Leon Kass, Mystic” (2004), Reason wonders if Kass’s philosophical musings are enough of a reason to condemn billions of people to a slow and painful death. Just like the alchemists, Reason argues, Kass’s vision is based upon ancient texts and his own subjective knee-jerk reactions, instead of researching the world around him. Reason postulates that this is the fundamental difference between a mystic and a scientist: The mystic is immune to impractical facts, consequences, and reality.

De Grey also argues against the bioconservative position. He rejects the idea that longer lives will somehow lower our appreciation of life. We will be able to start a new major when we are fifty years old, or a new career when we’re a hundred and fifty. The very fact that we have so little time causes us to experience “lock-in” in our careers and choices. This causes boredom and stress. The amount of time we lose switching to doing something we may enjoy a lot more is too radical, because we have so little time to begin with. Radical life extension seems more likely to actually cure the problems its critics claim it will cause (such as boredom, stress, or disenchantment with life).

Conclusion

Treatments for age-related diseases are on their way, and curing aging is big business. The first people are already getting early treatments, and the prognoses are positive. Society will have to adapt to the changes that come with these treatments. It is very important to explore options for adequately engaging public opinion in favor of curing age-related disease, to mitigate massive economic and human losses that these diseases currently cause, and to create the legislation and framework needed to implement these technologies in a fair, responsible, and sane way.

Bibliography

Bregman, Rutger (2013). Dromen is niet eng; Essay Pleidooi voor de utopie. De Groene Amsterdammer, jaar 137, week 20. https://www.groene.nl/artikel/pleidooi-voor-de-utopie.

Gladwell, Malcolm (2000). The Power of Context. In R.E. Miller & Spellmeyer (Eds.), The New Humanities Reader (Fifth Edition, pp. 148-167). Print.
 *** 
Stiglitz, J. E. (2012). Rent Seeking and the Making of an Unequal Society. In R.E. Miller & Spellmeyer (Eds.), The New Humanities Reader (Fifth Edition, pp. 148-167). Print.
 *** 

Johnson, Steven. ‘Emergence: The connected Lives of Ants, Brains, Cities, and Software’, 2001. In ‘The New Humanities Reader’, Richard E. Miller, Kurt Spellmeyer, Wadsworth, 2011, pp. 151 – 165

De Grey, Aubrey D. N. J. (2005). Resistance to debate on how to postpone ageing is delaying progress and costing lives. EMBO Reports, 6(Suppl 1), S49–S53. http://doi.org/10.1038/sj.embor.7400399

Kass, Leon (2004). Aging Research.  http://agingresearch.org/sage/Default.aspx?tabid=60

Reason (2004). Leon Kass, Mystic. FightAging.org. https://www.fightaging.org/archives/2004/04/leon-kass-mysti.php
 *** 
Parrish, Elizabeth (2015). Liz Parrish speaks at People Unlimited on transcending the aging paradigm with gene therapy. https://www.youtube.com/watch?v=87OUb8TBwX0
 *** 

Demian Zivkovic is the president of the Institute of Exponential Sciences  (Facebook  / Meetup) – an international transhumanist think tank / education institute comprised of a group of transhumanism-oriented scientists, professionals, students, journalists, and entrepreneurs interested in the interdisciplinary approach to advancing exponential technologies and promoting techno-positive thought. He is also an entrepreneur and student of artificial intelligence and innovation sciences and management at the university of Utrecht.

Demian and the IES have been involved in several endeavors, such as organizing lectures on exponential sciences, interviewing experts such as Aubrey de Grey, joining several of Mr. Stolyarov’s futurism panels, and spreading Death is Wrong – Mr. Stolyarov’s illustrated children’s book on indefinite life extension – in The Netherlands.

Demian Zivkovic is a strong proponent of healthy life extension and cognitive augmentation. His interests include hyperreality, morphological freedom advocacy, postgenderism, and hypermodernism. He is currently working on his ambition of raising enough capital to make a real difference in life extension and transhumanist thought.

“A Morte é um Erro” – Portuguese Translation of “Death is Wrong” – Translated by Eric Pedro Alvaro – Post by G. Stolyarov II

“A Morte é um Erro” – Portuguese Translation of “Death is Wrong” – Translated by Eric Pedro Alvaro – Post by G. Stolyarov II

The New Renaissance Hat
G. Stolyarov II
******************************

A free PDF version of A Morte é um Erro – the Portuguese translation of Death is Wrong – is now available for download from The Rational Argumentator. You can obtain your copy here and may spread it to Portuguese-speaking audiences as widely as you wish.

A Morte é um Erro was generously translated into Portuguese by Eric Pedro Alvaro.

Death_is_Wrong_Portuguese_CoverPaperback copies of A Morte é um Erro can be purchased in the following venues:

Createspace

Amazon

Kindle copies of A Morte é um Erro can be purchased on Amazon for $0.99.

***

Se você já se perguntou, “Por que as pessoas morrem?” então este livro é para você. A resposta é que não, a morte não é necessária, inevitável ou boa. Na verdade, a morte é um erro. A morte é uma inimiga de todos nós, que deve ser combatida com ciência, medicina e tecnologia. Este livro lhe apresenta os maiores, mais desafiantes e mais revolucionários movimentos para prolongar radicalmente o tempo de vida humano, para que você então simplesmente não precise morrer.

Você aprenderá sobre algumas plantas e animais com um tempo de vida incrivelmente longo, sobre recentes descobertas científicas em relação a ampliação do tempo de vida em humanos, e sobre simples e poderosos argumentos que podem refutar as comuns desculpas para a morte. Se você alguma vez já pensou que a morte é injusta e que ela deve ser derrotada, você não está sozinho. Leia este livro, e se torne parte desta importante busca na história da humanidade.

Este livro foi escrito pelo filósofo e futurólogo Gennady Stolyarov II e ilustrado pela artista Wendy Stolyarov. Com o intuito de lhe mostrar que, não importa quem é você e o que você pode fazer, sempre há uma forma de ajudar humanidade em sua batalha contra morte.

Refuting Ayn Rand’s “Immortal Robot” Argument – Article by G. Stolyarov II

Refuting Ayn Rand’s “Immortal Robot” Argument – Article by G. Stolyarov II

The New Renaissance HatG. Stolyarov II

******************************

Here I refute an argument that has been leveled against proponents of indefinite human longevity from a surprising direction – those sympathetic to the Objectivist philosophy of Ayn Rand. Some advocates of Ayn Rand’s philosophy believe that indefinite life would turn human beings into “immortal, indestructible robots” that, according to Ayn Rand, would have no genuine values. Both of these claims are false. Indefinite life would not turn humans into indestructible robots, nor would an indestructible robot with human abilities lack values or motivation for doing great things. In Ayn Rand’s own words, “Achieving life is not the equivalent of avoiding death.” (John Galt’s speech in For the New Intellectual, p. 135)

Rand’s “immortal robot” argument is found in “The Objectivist Ethics” (The Virtue of Selfishness, p. 15): “To make this point fully clear, try to imagine an immortal, indestructible robot, an entity which moves and acts, but which cannot be affected by anything, which cannot be changed in any respect, which cannot be damaged, injured or destroyed. Such an entity would not be able to have any values; it would have nothing to gain or to lose; it could not regard anything as for or against it, as serving or threatening its welfare, as fulfilling or frustrating its interests. It could have no interests and no goals.”

The “immortal robot” argument needs to be challenged because it originates from Ayn Rand, who otherwise espouses numerous rational ideas. I myself agree with most of the fundamental principles that Ayn Rand advocates. However, in some of her particular reasoning – at least, if applied to the wrong context – she can be off-target in such a way as to retard further progress. The often-leveled argument, derived by contemporary non-transhumanist Objectivists from the above-quoted passage, is that achieving indefinite longevity would turn human beings into Ayn Rand’s description of the “immortal, indestructible robot”.

In responding to Rand’s argument, several points can be made in relation to prolonging human life indefinitely and lifting the death sentence that hangs over all of us. First, at no point in time will human beings become the “immortal, indestructible robots” that Ayn Rand describes. The simple reason for this is that our existence is physical and contingent on certain physical prerequisites being fulfilled. The moment one of these physical prerequisites is lacking, our existence ceases. This will always be the case, even if we no longer have a necessary upper limit on our lifespans. For instance, biomedical advances that would greatly expand human lifespans – allowing periodic reversions to a more youthful biological state and therefore the possibility of an indefinite existence – would not turn humans into indestructible robots. There would still be the need to actively turn back biological processes of decay, and the active choice to pursue such treatments or not. People who live longer by successfully combating senescence could still get run over by a car or experience a plane crash. They would retain potential vulnerability to certain perils – such as death from accidents – although, as I have explained in “Life Extension and Risk Aversion”, they may be more diligent in seeking to greatly reduce the probability of such outcomes. If it is ever the case that death by senescence and the myriad diseases which kill many human beings today can be averted, then human beings will try to avert the other possibilities of death – for instance, by developing safer modes of transportation or engaging in fewer wars.

It is possible to significantly reduce the likelihood that one can be destroyed, without ever eliminating the theoretical potential of such destruction. Furthermore, because human beings have free will, they always have at least the hypothetical option of choosing to undermine the physical prerequisites of their own lives. In my view, no sane, rational being would actually choose to pursue that option, but the option is there nonetheless. For anybody who seeks to commit suicide by immediate or gradual means, or by refusing to take advantage of life-prolonging techniques once they become available, there is virtually nothing in the world that could prevent this, apart from rational persuasion (which may or may not be successful).

Even with indefinite longevity, human beings will always be vulnerable to some actual or hypothetical perils or poor choices. Moreover, when we manage to avoid one kind of peril, other kinds of perils may become more pressing as they come into the frame of awareness of longer-lived beings. If we do manage to live for hundreds of thousands of years, we will be far more subject to long-term geological changes and fluctuations of the Earth’s climate, such as the cycle of ice ages, whereas today humans do not live long enough to experience these massive shifts. Most of us today do not worry about the consequences of huge glaciers advancing over the continents, but humans who live for millennia will see this as a pressing problem for their own lifetimes. Likewise, the longer we live, the greater the likelihood that we will experience a global cataclysm, such as a supervolcano or an asteroid hitting the Earth. Human ingenuity and resources would need to be devoted toward confronting and even preventing these perils – a highly desirable outcome in general, since the perils exist irrespective of our individual lifespans, but most humans currently lack the long-term vision or orientation to combat them.

Moreover, the need to reject the “immortal robot” argument when discussing indefinite life extension does not stem solely from a desire to achieve philosophical correctness. Rather, we should recognize the potential for actually achieving meaningful, unprecedented longevity increases within our own lifetimes. For instance, the SENS Research Foundation is a nonprofit biogerontological research organization whose founder, Dr. Aubrey de Grey, has outlined an engineering-based approach to reversing the seven principal types of damage that accumulate in the human body with age. (SENS stands for “Strategies for Engineered Negligible Senescence”.) Dr. de Grey has stated that, with proper funding, there is approximately a 50 percent probability of these rejuvenation treatments being developed 20-25 years from now. (The 20-year figure is presented in this transcript from a recent NPR interview of Aubrey de Grey – quoted in “Discussing Science and Aging: Aubrey de Grey and Cynthia Kenyon at NPR” by Reason at FightAging.org.) The SENS Research Foundation is not the only entity pursuing radical life extension. Major commercial efforts toward research into reversing biological aging – such as Calico, created and funded by Google (now Alphabet, Inc.) – have been launched already. Thus, it is premature to conclude that death is a certainty for those who are alive today. Medical advances on the horizon could indeed turn many humans into beings who are still potentially vulnerable to death, but no longer subject to any upper limit on their lifespans.

It is therefore ill-advised to pin any ethical justifications for the ultimate value of human life to the current contingent situation, where it just so happens that human lifespans are finite because we have not achieved the level of technological advancement to overcome senescence yet. If such advances are achieved, common interpretations of the “immortal robot” argument and its derivative claims would suggest that life for human beings would transform from an ultimate value to some lesser value or to no value at all. This implication reveals a flaw in arguments that rely on the finitude of life and the inevitability of death. How is it that, by making life longer, healthier, and of higher quality (with less suffering due to the diseases of old age), humans would, in so doing, deprive life of its status as an ultimate value? If life is improved, it does not thereby lose a moral status that it previously possessed.

Yet another important recognition is that some animals have already attained negligible senescence. Their lifespans are de facto finite, but without a necessary upper limit. Suppose that evolution had taken a different course and rational beings had descended from tortoises rather than from primates. Then these rational beings would have negligible senescence without the need for medical intervention to achieve it. Would their lives thereby lack a type of value which the proponents of the “immortal robot” argument attribute to human lives today? Again, a conclusion of this sort illustrates a flaw in the underlying argument.

But suppose that a true immortal, indestructible robot could exist and be identical to human beings in every other respect. It would possess human biological processes and ways of thinking but be made of extremely strong materials that did not deteriorate or that automatically renewed themselves so as to rapidly, automatically repair any injury. Ayn Rand’s argument would still be mistaken. Even if death were not a possibility for such a being, it could still pursue and enjoy art, music, inventions, games – any activity that is appealing from the perspective of the senses, the intellect, or the general civilizing project of transforming chaos into order and transforming simpler orders into more complex ones.

The fear of death is not the sole motivator for human actions by far. Indeed, most great human accomplishments are a result of positive, not negative motivations. Rand acknowledged this when she wrote that “Achieving life is not the equivalent of avoiding death.” At least in the short term, you do not need to do much to avoid death. You could just sit there, stay out of trouble, eat, drink, keep warm, sleep – and you survive to the next day. But that is not a full life, according to Rand. Obviously, one needs to avoid death to have a full life. Survival is necessary, but it is not sufficient. Many thinkers sympathetic to the Objectivist school, such as Edward Younkins, Tara Smith, Douglas Den Uyl, Douglas Rasmussen, Tibor Machan, George Reisman, and Lester Hunt, have extended this insight to conclude that survival is not enough; one should also pursue flourishing. (Younkins provides an excellent overview of this perspective in “Flourishing and Happiness in a Nutshell”.)

I concur fully with the goal of flourishing and recognize the existence of numerous positive motivations besides mere survival. For example, the desire to see oneself create something, to witness a product of one’s mind become embodied in the physical reality, is a powerful motivation indeed. One can furthermore seek to take esthetic pleasure from a particular object or activity. This does not require even a thought of death. Moreover, to appreciate certain kinds of patterns in existence, which are present in art, in technology, and even in games, does not require any thought of death. Many people play games, even if those games do not contribute anything to their survival. This does not mean, however, that doing so is irrational; rather, it is another creative way to channel the activities of the human mind. Via games, the human mind essentially creates its own field of endeavor, a rule system within which it operates. By operating within that rule system, the mind exercises its full potential, whereas just by sitting there and only doing what is absolutely necessary to survive, the mind would have missed some essential part of its functioning.

Creating art and music, undertaking scientific discoveries, envisioning new worlds – actual and fictional – does not rely on having to die in the future. None of these activities even rely on the threat of death. The immortal, indestructible robot, of course, might not engage in precisely the same activities as we do today. It would probably not need to worry about earning its next meal by working for somebody else, but it could still paint a painting, just because it would like to see its mental processes – in this scenario, processes greatly resembling our own – have some kind of external consequence and embodiment in the external reality. Such external embodiment is a vital component of flourishing.

Fear of death is not the sole motivator for human action, nor the sole prerequisite for value, as Ayn Rand acknowledged. There is more to life than that. Life is not merely about survival and should be about the pursuit of individual flourishing as well. Survival is a necessary prerequisite, but, once it is achieved, an individual is free to pursue higher-order values, such as self-actualization. The individual would only be further empowered in the quest for flourishing and self-actualization in a hypothetical environment where no threats to survival existed.

While we will never be true immortal robots, such immortal robots could nonetheless flourish and truly achieve life. As a result, the “immortal robot” argument fails on multiple counts and is not a valid challenge to indefinite life extension.

This essay may be freely reproduced using the Creative Commons Attribution Share-Alike International 4.0 License, which requires that credit be given to the author, G. Stolyarov II. Find out about Mr. Stolyarov here.